Answers are grounded in this paper and cite their sources.
Systematic review reveals shared molecular pathways driving muscle wasting in peripheral arterial disease, highlighting the need for targeted therapies alongside exercise and revascularization.
Sarcopenia and lower extremity PAD have musculoskeletal consequences that directly impair patients' quality of life and prognosis. Although PAD is primarily a vascular disease, all etiological factors of sarcopenia identified so far are present in PAD. Indeed, both sarcopenia and PAD are accompanied by oxidative stress, skeletal muscle mitochondrial impairments, inflammation, inhibition of specific pathways regulating muscle synthesis or protection (i.e. IGF-1, RISK, and SAFE), and activation of molecules associated with muscle degradation. To date, besides revascularization, the best therapeutic strategy includes exercise, but approaches targeting the underlying mechanisms still deserve further studies.
No takes yet. Share an insight, caveat, or question.
Pizzimenti et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: